Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Applied Bio

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 22 June 2001:
Vol. 292. no. 5525, pp. 2231 - 2233
DOI: 10.1126/science.292.5525.2231a
Prev | Table of Contents | Next

News of the Week

CANCER RESEARCH:
Why Some Leukemia Cells Resist STI-571

Jean Marx

The antileukemia drug known as Gleevec or STI-571 has been heralded as the vanguard of a new generation of cancer chemotherapy agents, designed specifically to counteract the biochemical changes that make cells cancerous. Yet STI-571 shares an unfortunate characteristic with older, conventional drugs. Patients with advanced disease often relapse; their tumor cells become resistant and eventually grow out of control. Results published online by Science on 21 June (www.sciencexpress.org) now explain why this happens in STI-571, and perhaps point the way to improved therapies.

Read the Full Text

ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)